Physician profile
William Skinner
NPI 1821104605
$1,251.08
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $194 · 2021: $190 · 2022: $50.94 · 2023: $30.97 · 2024: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $537 · Food and Beverage: $61.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $537.20 |
| Food and Beverage | $61.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $537.20 | 2024 | Inpefa |
| Abbvie INC. | $150.97 | 2021-2022 | |
| Amgen INC. | $145.82 | 2019-2020 | |
| Lilly USA, LLC | $84.40 | 2020-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $34.04 | 2019-2021 | |
| Pfizer INC. | $32.71 | 2019 | |
| Glaxosmithkline, LLC. | $31.02 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $29.86 | 2019 | |
| Vanda Pharmaceuticals INC. | $29.01 | 2020 | |
| Sanofi-Aventis U.S. LLC | $24.82 | 2020 | |
| Depuy Synthes Sales INC. | $24.80 | 2021 | |
| Genentech USA, INC. | $22.80 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.67 | 2020 | |
| Amarin Pharma, INC. | $18.21 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.32 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.21 | 2019 | |
| Circassia INC. | $14.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.